# US 2014/0193485 A1 · Orally administrable liposomally encapsulated reduced glutathione, with ace inhibitors for reversal and prevention of oxidation of cholesterol and of low density lipoprotein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193485 A1
- Document ID: US20140193485A1
- Status: Published application
- Kind: A1
- Application number: 14/173,558
- Filed: 2014-02-05
- Published: 2014-07-10
- Earliest claimed: 2004-11-07
- Assignees: Your Energy Systems, LLC
- Applicants: Your Energy Systems, LLC
- Inventors: Frederick Timothy Guilford
- Web page: https://patentgrep.com/patent/US20140193485A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 38/05: Dipeptides
- A61K 38/063: {Glutathione}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 31/12: Antivirals
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
reduced glutathione in a liposomal formulation capable of administration orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and
an ACE inhibitor.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23, further comprising:
selenium.

### Claim 25

A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
reduced glutathione in a liposomal formulation capable of administration orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and
lisinopril.

### Claim 26 (depends on 25)

The pharmaceutical composition according to claim 25, further comprising:
selenium.